Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer

Table 4 Survival data (a) and analysis of the correlation between MN and NPB yields and patient survival (b)

a
	3 years [95%-CI]				5 years [95%-CI]
Recurrence-free survival	74% [67–82%]				72% [64–80%]
Locoregional recurrence-free survival	95% [91–99%]				92% [87–98%]
Distant metastasis-free survival	74% [67–82%]				71% [63–80%]
Cancer-specific survival	85% [79–92%]				76% [67–86%]
b
	MN/BNL				NPB/BNL
	3 Gy in vitro		End RCT (50.4Gy)		3 Gy in vitro		End RCT (50.4Gy)
	HR [CI]	P	HR [CI]	P	HR [CI]	P	HR [CI]	P
Recurrence-free survival	0.9 [0.4–1.7]	0.70	1.5 [0.7–3.0]	0.26	1.6 [0.8–3.3]	0.64	1.6 [0.8–3.3]	0.18
Locoregional recurrence-free survival	1.3 [0.3–5.6]	0.70	1.0 [0.2–3.8]	0.95	1.4 [0.4–5.8]	0.62	1.2 [0.3–4.9]]	0.78
Distant metastasis-free survival	0.6 [0.3–1.3]	0.21	1.3 [0.7–2.7]	0.43	1.3 [0.7–2.6]	0.46	1.9 [0.9–3.8]	0.09
Cancer-specific survival	0.6 [0.3–1.4]	0.22	1.3 [0.6–2.9]	0.57	1.4 [0.6–3.1]	0.47	1.9 [0.8–4.3]]	0.14

MN micronuclei, BNL binuclear lymphocytes, NPB nucleoplasmatic bridges, RCT radiochemotherapy

ISSN: 1471-2407